Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 14/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075500 | 1.00 | KCNA5 (0.72) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14267601 | 0.84 | KCNA5 (1.00) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5072752 | 0.83 | KCNA5 (0.69) | KCNA5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL14498263 | 0.83 | KCNA5 (0.69) | KCNA5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL12201554 | 0.80 | KCNA5 (1.00) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14267608 | 0.80 | KCNA5 (1.00) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14267642 | 0.79 | KCNA5 (0.85) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL12202039 | 0.79 | KCNA5 (0.85) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14267633 | 0.79 | KCNA5 (1.00) | KCNA5ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL12435747 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235664-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| CN-1247544-C | Anthranilic acid amides with heteroarylsulfonyl side chains and their use as antiarrhythmic active substances | SANNOFFE AVENTIS DEUTSCHLAND G (DE) | 2006-03-29 | — | — | CN | disclosed |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6903216-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| CN-1529695-A | Anthranilic acid amides with heteroarylsulfonyl side chains, method for the production thereof, use thereof as medicaments or diagnostic agents, and pharmaceutical preparations containing said compounds | ������ҽҩ�¹�����˾ | 2004-09-15 | — | — | CN | disclosed |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | KCNJ2, KCNQ5, KCNH1 | KCNA5 6/4885ALDH1A1 1867/4885KDM4E 221/4885 |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | KCNJ2, KCNQ5, KCNH1 | KCNA5 6/4885ALDH1A1 1650/4885KDM4E 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.